Pulmonary hypertension in adults on chronic hemodialysis: prevalence, causes, and prognosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective multicenter longitudinal observational study of adults with end-stage renal disease receiving chronic extracorporeal hemodialysis. Participants receive a standardized screening echocardiogram the day after an intermediate dialysis session to estimate pulmonary hypertension probability, and those at high risk undergo confirmatory right heart catheterization, lung imaging, and respiratory function testing. The protocol measures biomarkers such as angiopoietin-2 and quantifies right ventricular function (TAPSE) to explore pathogenesis and prognostic value. The study also examines the hemodynamic effects of high-flow arteriovenous fistulas and volume overload with clinical follow-up at baseline, 6 months, and 12 months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged between 18 and 75 years
* Patients on stable extracorporeal hemodialysis for at least 6 months
* Dialysis frequency of two or three times per week
* Ability to provide written informed consent

Exclusion Criteria:

* WHO functional class IV
* Presence of valvular or congenital heart disease
* Acute infections within the month preceding the cardiological evaluation

Where it's running

• Fondazione IRCCS Policlinico San Matteo di Pavia
  Pavia, Lombardy, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER

  This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.

  Recruiting Early Phase 1 Xiamen Cardiovascular Hospital, Xiamen University · Xiamen, Fujian · NCT07662655

• Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.

  Recruiting at 4 sites Peking Union Medical College Hospital · Guangzhou, Guangdong and 3 other locations · NCT07653958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.